Ad hoc analysis of behavior and time as co-variates of the Thai phase III efficacy trial: RV 144

BACKGROUND: The Thai phase III HIV vaccine trial's modest efficacy (VE 31.2% 95% CI 1.1, 51.2) represents the first demonstration that a vaccine can protect against HIV acquisition. Baseline variables of age, gender, marital status, and risk did not modify vaccine efficacy (VE). Here we explore...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Robb, Merlin L., Rerks-Ngarm, Supachai, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Kunasol, Prayura, Khamboonruang, Chirasak, Thongcharoen, Prasert, Morgan, Patricia, Benenson, Michael, Paris, Robert M., Chiu, Joseph, Adams, Elizabeth, Francis, Donald, Gurunathan, Sanjay, Tartaglia, Jim, Gilbert, Peter, Stablein, Don, Michael, Nelson L., Kim, Jerome H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3530398/
https://ncbi.nlm.nih.gov/pubmed/22652344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(12)70088-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados